In this captivating episode, David engages in a thought-provoking conversation with none other than Joshua White, the visionary CEO behind the Fireside Project. This groundbreaking initiative has ushered in a new era of support and safety within the realm of psychedelics, as it introduces the world's first real-time psychedelic peer support line.
Similar Posts
MindMed Releases LSD for Anxiety Data ! (MNMD, MMED)
Get your 20%-off tickets to the Catalyst Psychedelics Summit in Kingston Ontario, May 20th-23rd:
www.eventbrite.ca/e/153409882087/?discount=SPOTLIGHT20
Join our Newsletter (scroll to the bottom of the page and sign up):
https://psychedelicspotlight.com/
Follow us on Twitter:
The Psychedelic Investor: @PSYCBiz
Psychedelic Spotlight: @PsycSpotlight
Follow us on Instagram:
@psycbiz
@psycspotlight
❗❗❗ The Psychedelic Investor will be changing its name to PSYC Business very soon.
Stay tuned for more updates!
In today’s episode, we discuss MindMed (Nasdaq: MNMD, NEO:MMED) and its Phase 2 LSD Trial Treating Anxiety Results.
MindMed (Nasdaq: MNMD, NEO:MMED) finally gave the world a glimpse into its LSD-as-medicine project today.
Speaking at the highly anticipated PSYCH Symposium in London, researchers Prof. Matthias Liechti and Dr. Friederike Holze presented topline data of a Phase 2, double-blind, placebo-controlled study, attempting to treat anxiety disorders with LSD in 46 patients. Patients received 200 µg (micrograms) of LSD, which is considered a large dose.
The results were very positive, though perhaps not paradigm shifting — yet.
The primary endpoint of the study was the reduction in anxiety levels 16 weeks after the administration of LSD. They measured this using a questionnaire called the State Trait Anxiety Inventory, better known by its acronym STAI. In short, a person can have a score between 0 and 63, with the higher the score, the worse the anxiety.
The study found that 65% of patients saw their anxiety levels drop by at least 30% from where they were before treatment, 16 weeks after dosing. This compared to only 9% of patients in the placebo arm reaching that 30% level. The average reduction in the STAI was 16.2 points.
Importantly, there was only one serious adverse event in the trial, which consisted of “acute transient anxiety and delusions” during the LSD experience. It does not appear that this patient had any troubles once the effects wore off. In sum, the administration of large doses of LSD appears to be very safe, even if one person did have a particularly bad experience during the dosing.
Furthermore, when looking at secondary variables that measure depression, anxiety and other major psychiatric symptoms (Hamilton Depression Scale, Beck Depression Index, Symptom-Check-List-90-R) the results “showed similarly rapid and sustained responses consistent with a lasting treatment effect.”
In sum, according to MindMed, the topline data demonstrates “the significant, rapid, durable, and beneficial effects of LSD and potential to safely mitigate symptoms of anxiety and depression.”
Interested in reading the article? Click here: 👇
MindMed’s Phase 2 LSD Trial Treating Anxiety Was a Success
https://psychedelicspotlight.com/mindmed-lsd-anxiety-phase-2-trial-psych-symposium/
#MindMed #Anxiety #MNMD
Why the Psychedelic Drug Market is Experiencing Major Growth
David Flores, CEO of Global Trac Solutions (PSYC), joins Cheddar…
MindMed 2021 Year-End Conference Call and Earnings: Big Updates for MNMD Stock
MindMed 2021 Year-End Conference Call and Earnings: Big Updates for MNMD Stock
Join our Newsletter (scroll to the bottom of the page and sign up): https://psychedelicspotlight.com/psychedelic-news/industry/
All Psychedelic Stock investors should take the time to listen to the conference calls of the companies they are investing in. That is doubly important for year-end calls, as often information is divulged on the direction of the company. If you are invested in MNMD or MMED stock, you need to listen to this call.
Follow us on Twitter:
The Psychedelic Investor: @psycInvestor
James: @Psy_Invest
Maria: @psy_holy
Psychedelic Spotlight: @PsycSpotlight
Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight
To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/
Meet Kevin O’Leary, Rober Barrow, Daniel Carcillo and other psychedelic leaders @ the Benzinga Psychedelics Capital Conference.on April 19 @ Fontainebleau Hotel, Miami!
https://www.eventbrite.com/e/benzinga-psychedelics-capital-conference-spring-2022-tickets-238697028237?discount=PSYCHSPOTLIGHT15&fbclid=IwAR3tJFhoVfVWZvAyQuWSLEo3kJSmaq8VGnQQPz04NMhG3g7rHtSmRSAUq64
COUPON CODE: PSYCHSPOTLIGHT15
Interested in going to Malta for Plant Medicine Week April 5th-8th? Get discounted tickets here: https://tickets.plantmedicineweek.com/attendance/event/index/41436/EN?promocodes=PSYC
In this MindMed 2021 conference and earnings call, we gained important insights into the company’s many projects. These include: Project Lucy, which attempts to treat Anxiety using LSD; Project Angie, attempting to treat pain with LSD; Project Layla, attempting to treat addiction with 18-MC, and much more.
The company gives some updates on the science of psychedelics, as well as their hiring strategy and financial updates. MindMed is a company working on treating mental health conditions with psychedelics. They are a leading player in the shroom boom, and they aim to commercialize psychedelics as medicines.
Some of the questions MindMed is trying to answer are:
Can Psychedelics treat Mental Health conditions?
Can Psychedelics treat depression?
Can Psychedelics treat anxiety?
Can Psychedelics treat ADHD?
Can Psychedelics help with Autism?
Can Psychedelics help treat pain?
#MindMed #MNMD #MindMedStocks
This Week in Psychedelic Stocks [Big UPDATES ON MMEDF, CMPS, FTRPF, and ATAI]
Hello Psychedelic Investors! In this new segment entitled “This Week in Psychedelic Stocks”, we’ll see some news on MindMed (MMED / MMEDF), Compass Pathways (CMPS), Atai Life Sciences, and Field Trip Health (FTRPF/ FTRP).
We will cover the latest developments in the field writ large,
This means we will cover any stories that affect the all the companies in this field, as well as company specific developments.
Time Stamps
0:00 – Intro
0:56 – California Legalizing Psychedelics?
2:09 – Texas Legalizing Psychedelics?
3:33 – STOP LICKING TOADS DUDE
4:05 – MindMed Stock Updates (MMED / MMEDF)
9:13 – Compass Pathways Stock Updates (CMPS)
13:25 – Atai Life Sciences Update
17:05 – Field Trip Health Stock Updates (FTRPF/ FTRP)
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MindmedStock #PsychedelicStocks
Psychedelic Spotlight Interview with Joshua White
In this episode of the Psychedelic Spotlight podcast, we speak…